These guidelines were commissioned by the British Association of Dermatologists Therapy, Guidelines and Audit Subcommittee. Members of the committee are A.D.Ormerod (Chairman), A.S.Highet, D.Mehta, R.H.Meyrick Thomas, C.H.Smith, J.C.Sterling and A.Anstey. Conflicts of interest: No additional funding was received by the authors of these guidelines to support this work. None of the authors has a conflict of interest to declare.
Guidelines for prescribing azathioprine in dermatology
Article first published online: 9 DEC 2004
British Journal of Dermatology
Volume 151, Issue 6, pages 1123–1132, December 2004
How to Cite
ANSTEY, A.V., WAKELIN, S. and REYNOLDS, N.J. (2004), Guidelines for prescribing azathioprine in dermatology. British Journal of Dermatology, 151: 1123–1132. doi: 10.1111/j.1365-2133.2004.06323.x
- Issue published online: 9 DEC 2004
- Article first published online: 9 DEC 2004
- Accepted for publication 14 May 2004
Azathioprine has been available as an immunosuppressive agent for over 40 years, and current routine usage in dermatology is not restricted to licensed indications. Advances in understanding the metabolic fate of azathioprine have led to significant changes in prescribing practice and toxicity monitoring by U.K. dermatologists. The current state of knowledge concerning the use of azathioprine in dermatology is summarized, with identification of strength of evidence. Clinical indications and contraindications for azathioprine usage in dermatology are identified. Evidence-based recommendations are made for routine safety monitoring of patients treated with azathioprine, including pretreatment assessment of red blood cell thiopurine methyltransferase activity.